Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Pfizer

Status: Completed

Conditions: Metastatic Renal Cell Carcinoma

Treatments: Drug: SUTENT

Study type: Observational

Funder types: Industry

Identifiers

NCT00684645

A6181171

Details and patient eligibility

About

Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®. Secondary objectives: treatment response, hypothyroidism prevalence.The efficacy will be assessed using the Objective Response Rate, Time to Progression based on the RECIST criteria and the ECOG performance data.

Full description

180 patients will be enrolled at 20 key oncological centres, the sample size is sufficient for exploratory analysis.

Enrollment: 186 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with advanced or metastatic renal cell carcinoma.

Exclusion criteria

• No previous cytokines therapy.

Trial design

186 participants in 1 patient group

Patients treated with SUTENT®

Description:

Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.

Treatment:

Drug: SUTENT